Effects of nitric oxide-related compounds in the acute ketamine animal model of schizophrenia

BACKGROUND: Better treatments for schizophrenia are urgently needed. The therapeutic use of the nitric oxide (NO)-donor sodium nitroprusside (SNP) in patients with schizophrenia has shown promising results. The role of NO in schizophrenia is still unclear, and NO modulation is unexplored in ketamine...

Descripción completa

Detalles Bibliográficos
Autores principales: Kandratavicius, Ludmyla, Balista, Priscila Alves, Wolf, Daniele Cristina, Abrao, Joao, Evora, Paulo Roberto, Rodrigues, Alfredo Jose, Chaves, Cristiano, Maia-de-Oliveira, Joao Paulo, Leite, Joao Pereira, Dursun, Serdar Murat, Baker, Glen Bryan, Guimaraes, Francisco Silveira, Hallak, Jaime Eduardo Cecilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354998/
https://www.ncbi.nlm.nih.gov/pubmed/25887360
http://dx.doi.org/10.1186/s12868-015-0149-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354998/
https://www.ncbi.nlm.nih.gov/pubmed/25887360
http://dx.doi.org/10.1186/s12868-015-0149-3

Ejemplares similares